What about a Cheaper "Tin" ACA Plan?

Article

The ACA requires participating insurers to offer plans ranked by the quality and cost of their offerings. The cheapest is labeled bronze, then silver, gold, and platinum. Some policymakers have proposed creating a still cheaper plan that would protect someone from health care bankruptcy, but have high out-of-pocket costs for care.

(Click the play button on the audio player above to listen to this segment of the ACA panel discussion)

This HCPLive audio panel discussion features:

  • Joel Zinberg MD, JD, Associate Clinical Professor of Surgery at Mount Sinai Hospital in New York City
  • David Sandman PhD, Senior Vice President of the New York State Health Foundation
  • Patrick Cronin, New Jersey organizing director for “Get Covered America” a nonprofit with a federal contract to help people sign up for coverage
  • Tom Wilson (moderator), a partner at Kaufman Zita Group and former chairman of the NJ Republican State Committee

The panelists look at how well the ACA is working and discuss whether it is politically vulnerable.

The ACA requires participating insurers to offer plans ranked by the quality and cost of their offerings. The cheapest is labeled bronze, then silver, gold, and platinum. Some have proposed creating a still cheaper plan that would protect someone from health care bankruptcy, but have high out-of-pocket costs for care. Would that increase ACA enrollment?

Sandman says most people opt for a silver plan, and that such plans give good value. Cronin says price is important, but so is quality. Zinberg says that in NY, the bar has always been set high for what health insurance plans must cover but that under the ACA a bare-bones plan might be useful.

“You get what you pay for a copper or tin plan might be better than nothing, but you would very much be under-insured and still very vulnerable” Sandman says.

But Zinberg said the idea could work.

“A catastrophic plan really offers a very good way to insure people at a lower cost. . . particularly for younger people,” Zinberg says.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.